Home' Australian Pharmacist : September 2011 Contents Vol. 30 -- September #09, 2011
of only 5--20% in this subgroup
Poor communication can easily lead
to confusion and poor adherence
with therapy, misconceptions about
COPD and unrealistic expectations
of treatment. Pharmacists play an
important role in helping patients
to understand the nature of the
disease, the potential benefits of
treatment, addressing concerns
about potential adverse effects,
delivering smoking cessation advice
and encouraging patients to develop
a routine for taking their prescribed
1. Wise RA. Chronic obstructive pulmonary disease.
In: Porter RS, ed. Merck Manual [online].
2. Hanania NA, Sharma G, Sharafkhaneh A. COPD in
the elderly patient. Semin Respir Crit Care Med.
3. Access Economics. Economic impact of COPD and
cost effective solutions. Report prepared by Access
Economics for The Australian Lung Foundation.
Brisbane: The Australian Lung Foundation; 2008.
4. American Pharmacists Association. White
paper on expanding the role of pharmacists in
chronic obstructive pulmonary disease: American
Pharmacists Association Foundation. J Am Pharm
Assoc. 2011; 51(2):203--11.
5. Chapman KR. Chronic obstructive pulmonary disease:
are women more susceptible than men? Clin Chest
Med. 2004; 25(2):331--41.
6. Global Strategy for the Diagnosis, Management and
Prevention of COPD, Global Initiative for Chronic
Obstructive Lung Disease (GOLD) [online]. 2010.
7. McKenzie DK, Abramson M, Crockett AJ, et al. on
behalf of The Australian Lung Foundation. The COPD-X
Plan: Australian and New Zealand Guidelines for the
management of Chronic Obstructive Pulmonary Disease
2010 [online]. Version 2.22 May 2010.
8. Tinkelman DG, Price DB, Nordyke RJ, et al.
Misdiagnosis of COPD and asthma in primary care
patients 40 years of age and over. J Asthma. 2006;
9. Mannino DM, Buist AS, Vollmer WM. Chronic
obstructive pulmonary disease in the older adult:
what defines abnormal lung function? Thorax. 2007;
10. Abramson M, Glasgow N, McDonald C. Managing
chronic obstructive pulmonary disease. Aust Prescr.
11. Chronic obstructive pulmonary disease [revised
2009 Oct]. In: eTG complete [CD-ROM]. Melbourne:
Therapeutic Guidelines; 2011 Mar, etg33.
12. Lee TA, Pickard AS, Au DH, et al. Risk for death
associated with medications for recently diagnosed
chronic obstructive pulmonary disease. Ann Intern Med.
13. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics
and risk of major adverse cardiovascular events in
patients with chronic obstructive pulmonary disease:
a systematic review and meta-analysis. JAMA. 2008;
14. Celli B, Decramer M, Leimer I, et al. Cardiovascular
safety of tiotropium in patients with COPD. Chest.
15. Singh S, Loke YK, Enright PL, et al. Mortality associated
with tiotropium mist inhaler in patients with chronic
obstructive pulmonary disease: systematic review and
meta-analysis of randomised controlled trials. BMJ.
16. Cates CJ. Safety of tiotropium. BMJ. 2011; 342:d2970.
17. Dzierba AL, Jelic S. Chronic obstructive pulmonary
disease in the elderly: an update on pharmacological
management. Drugs Aging. 2009; 26(6):447--56.
18. Orvoen-Frija E, Benoit M, Catto M, et al. Chronic
obstructive pulmonary disease (COPD) in the elderly.
Rev Mal Respir. 2010; 27(8):855--73.
19. Valente S, Pasciuto G, Bernabei R, et al. Do we need
different treatments for very elderly COPD patients?
Respiration. 2010; 80(5):357--68.
20. Afonso AS, Verhamme KM, Stricker BH, et al. Inhaled
anticholinergic drugs and risk of acute urinary
retention. BJU Int. 2010 Sep 29. doi: 10.1111/j.1464-
21. Stephenson A, Seitz D, Bell CM, et al. Inhaled
anticholinergic drug therapy and the risk of acute
urinary retention in chronic obstructive pulmonary
disease: a population-based study. Arch Intern Med.
22. Hammerlein A, Muller U, Schulz M. Pharmacist-led
intervention study to improve inhalation technique in
asthma and COPD patients. J Eval Clin Pract. 2011;
23. Pleasants RA, Haden D. An update on chronic
obstructive pulmonary disease. Consult Pharm. 2005;
24. Cosio BG, Agusti A. Update in chronic obstructive
pulmonary disease 2009. Am J Respir Crit Care Med.
25. Krigsman K, Nilsson JL, Ring L. Refill adherence for
patients with asthma and COPD: comparison of a
pharmacy record database with manually collected
repeat prescriptions. Pharmacoepidemiol Drug Saf.
26. Cramer JA, Bradley-Kennedy C, Scalera A. Treatment
persistence and compliance with medications for
chronic obstructive pulmonary disease. Can Respir J.
27. Breekveldt-Postma NS, Koerselman J, Erkens JA, et al.
Enhanced persistence with tiotropium compared with
other respiratory drugs in COPD. Respir Med. 2007;
The Victorian College of Pharmacy has been proudly educating
Victorian pharmacists since 1881. Today, as the Faculty of Pharmacy and
Pharmaceutical Sciences at Monash University, we continue to maintain
our position as one of the country's pre-eminent pharmacy education
and research institutions.
A proud tradition of philanthropy and giving has been the cornerstone
of our success. You can continue this tradition -- and help us shape the
future of pharmacy.
A bequest in your Will is a valued gift and can be directed towards a
particular area of pharmacy education and/or research.
For more information please contact Anne Gribbin, Director,
Victorian College of Pharmacy Foundation
Telephone +61 3 9903 9507
email at email@example.com or
Your generosity can help
shape the future of pharmacy
CRICOS Provider: Monash University 00008C
Links Archive October 2011 August 2011 Navigation Previous Page Next Page